The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases

被引:42
作者
Pang, B. [2 ,3 ]
Matthias, D. [4 ]
Ong, C. W. [2 ]
Dhewar, A. N. [3 ]
Gupta, S. [3 ]
Lim, G. L. [3 ]
Nga, M. E. [3 ]
Seet, J. E. [3 ]
Qasim, A. [3 ]
Chin, T. M. [2 ,5 ]
Soo, R. [2 ,5 ]
Soong, R. [2 ,3 ]
Salto-Tellez, M. [1 ,2 ]
机构
[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland
[2] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore
[3] Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Pathol, Singapore, Singapore
[4] Univ Pittsburgh, Dept Pathol & Lab Med, Pittsburgh, PA USA
[5] Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Haematol Oncol, Singapore, Singapore
关键词
EGFR mutation; non-small cell lung cancer; tyrosine kinase inhibitors; Sanger sequencing; cytological specimens; FACTOR RECEPTOR MUTATIONS; GEFITINIB; THERAPY; TRIAL; ADENOCARCINOMA; INFORM;
D O I
10.1111/j.1365-2303.2012.01000.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
B. Pang, D. Matthias, C.W. Ong, A.N. Dhewar, S. Gupta, G.L. Lim, M.-E. Nga, J.E. Seet, A. Qasim, T.-M. Chin, R. Soo, R. Soong and M. Salto-Tellez The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratorys analysis of 670 cases Objectives: To compare the rejection rates of non-small cell lung cancer (NSCLC) samples obtained by differing sampling methods for testing by Sanger sequencing for epidermal growth factor receptor (EGFR) mutations. To assess the association between unsatisfactory outcomes and the quantity of DNA extracted from cytological versus histological samples. Methods: Six hundred and seventy NSCLC samples referred to our centre from 2008 to 2010 were reviewed as a consequence of sample rejection, presence of EGFR mutations, cytological versus histological sampling methods, DNA quantity and the unsatisfactory genotyping rate. Results: Eighty samples were rejected for testing in similar proportions of histological and cytological samples (11.9% versus 10.9%) usually (n = 75) because the amount of cellular material was judged insufficient in small biopsies or cytology samples. The remaining 590 samples on which EGFR testing was attempted yielded 51 (8.6%) unsatisfactory test outcomes caused by failure of the polymerase chain reaction (PCR) (n = 47 cases), uninterpretable Sanger chromatograms (n = 3 cases) and insufficient DNA extracted for PCR (n = 1 case). The difference in rates of unsatisfactory outcomes between cytological samples (seven of 147 samples or 4.7%) versus tissue samples (44 of 443 samples or 9.9%) was clinically relevant but not statistically significant (MannWhitney test; P < 0.081). There was no association between the concentration of DNA extracted and the likelihood of an unsatisfactory analysis; which was similar in all types of sections (large and small) while 0% of 37 cytology slides were unsatisfactory. Conclusions: Utilizing cytology samples for EGFR testing avoids unnecessary patient re-biopsing and yields a clinically superior satisfactory rate to the overall satisfactory rate of tissue biopsies of NSCLC. The quality rather than quantity of DNA extracted may be a more important determinant of a satisfactory result.
引用
收藏
页码:229 / 236
页数:8
相关论文
共 21 条
[1]   EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations:: one-third of doublets occur at five pairs of amino acids [J].
Chen, Z. ;
Feng, J. ;
Saldivar, J-S ;
Gu, D. ;
Bockholt, A. ;
Sommer, S. S. .
ONCOGENE, 2008, 27 (31) :4336-4343
[2]   Detection of epidermal growth factor receptor variations by partially denaturing HPLC [J].
Chin, Tan Min ;
Anuar, Diyanah ;
Soo, Ross ;
Salto-Tellez, Manuel ;
Li, Wei Qi ;
Ahmad, Baidah ;
Lee, Soo Chin ;
Goh, Boon Cher ;
Kawakami, Kazuyuki ;
Segal, Amanda ;
Iacopetta, Barry ;
Soong, Richie .
CLINICAL CHEMISTRY, 2007, 53 (01) :62-70
[3]   Seize the Opportunity Underutilization of Fine-Needle Aspiration Biopsy to Inform Targeted Cancer Therapy Decisions [J].
Clark, Douglas P. .
CANCER CYTOPATHOLOGY, 2009, 117 (05) :289-297
[4]   Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: Standardization for use in the clinical trial setting [J].
Eberhard, David A. ;
Giaccone, Giuseppe ;
Johnson, Bruce E. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) :983-994
[5]   Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues [J].
Gridelli, C. ;
De Marinis, F. ;
Di Maio, M. ;
Cortinovis, D. ;
Cappuzzo, F. ;
Mok, T. .
LUNG CANCER, 2011, 72 (01) :3-8
[6]   First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung [J].
Han, Ji-Youn ;
Park, Keunchil ;
Kim, Sang-We ;
Lee, Dae Ho ;
Kim, Hyae Young ;
Kim, Heung Tae ;
Ahn, Myung Ju ;
Yun, Tak ;
Ahn, Jin Seok ;
Suh, Cheolwon ;
Lee, Jung-Shin ;
Yoon, Sung Jin ;
Han, Jong Hee ;
Lee, Jae Won ;
Jo, Sook Jung ;
Lee, Jin Soo .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1122-1128
[7]   American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy [J].
Keedy, Vicki Leigh ;
Temin, Sarah ;
Somerfield, Mark R. ;
Beasley, Mary Beth ;
Johnson, David H. ;
McShane, Lisa M. ;
Milton, Daniel T. ;
Strawn, John R. ;
Wakelee, Heather A. ;
Giaccone, Giuseppe .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :2121-2127
[8]   Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].
Maemondo, Makoto ;
Inoue, Akira ;
Kobayashi, Kunihiko ;
Sugawara, Shunichi ;
Oizumi, Satoshi ;
Isobe, Hiroshi ;
Gemma, Akihiko ;
Harada, Masao ;
Yoshizawa, Hirohisa ;
Kinoshita, Ichiro ;
Fujita, Yuka ;
Okinaga, Shoji ;
Hirano, Haruto ;
Yoshimori, Kozo ;
Harada, Toshiyuki ;
Ogura, Takashi ;
Ando, Masahiro ;
Miyazawa, Hitoshi ;
Tanaka, Tomoaki ;
Saijo, Yasuo ;
Hagiwara, Koichi ;
Morita, Satoshi ;
Nukiwa, Toshihiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388
[9]  
Marchetti A, 2006, NEW ENGL J MED, V354, P526
[10]   Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].
Mitsudomi, Tetsuya ;
Morita, Satoshi ;
Yatabe, Yasushi ;
Negoro, Shunichi ;
Okamoto, Isamu ;
Tsurutani, Junji ;
Seto, Takashi ;
Satouchi, Miyako ;
Tada, Hirohito ;
Hirashima, Tomonori ;
Asami, Kazuhiro ;
Katakami, Nobuyuki ;
Takada, Minoru ;
Yoshioka, Hiroshige ;
Shibata, Kazuhiko ;
Kudoh, Shinzoh ;
Shimizu, Eiji ;
Saito, Hiroshi ;
Toyooka, Shinichi ;
Nakagawa, Kazuhiko ;
Fukuoka, Masahiro .
LANCET ONCOLOGY, 2010, 11 (02) :121-128